Prime Medicine (PRME) Leases (2021 - 2026)

Prime Medicine (PRME) has 6 years of Leases data on file, last reported at $123.3 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 1661.91% year-over-year to $123.3 million; the trailing twelve-month figure through Mar 2026 stood at $123.3 million (up 1661.91% YoY), and the FY2025 full-year result was $126.2 million, up 167.57% from the prior year.
• Leases for Q1 2026 stood at $123.3 million, down from $126.2 million in the prior quarter.
• Across five years, Leases topped out at $126.2 million in Q4 2025 and bottomed at $7.0 million in Q1 2025.
• The 5-year median for Leases is $32.3 million (2022), against an average of $52.9 million.
• The widest annual swing landed in 2025, when Leases slumped 84.41%; it then jumped 1661.91% in 2026.
• A 5-year view of Leases shows it stood at $29.5 million in 2022, then sank by 52.81% to $13.9 million in 2023, then soared by 238.25% to $47.2 million in 2024, then soared by 167.57% to $126.2 million in 2025, then decreased by 2.25% to $123.3 million in 2026.
• The last three Leases figures came in at $123.3 million (Q1 2026), $126.2 million (Q4 2025), and $117.9 million (Q3 2025), per Business Quant data.

Peer Comparison